<u>Procedure</u> NS5A Genotype NS5A Resistance	<u>Result</u> Mix la and lb See Note f	<u>Units</u>	<u>Ref Interval</u>	17-053-104039	Reported/ <u>Collected Received Verified</u> <u>92-Feb-17</u> <u>22-Feb-17</u> <u>22-Feb-17</u> 10:14:00 10:15:00 10:21:08 <u>922-Feb-17</u> <u>22-Feb-17</u> <u>22-Feb-17</u> 10:14:00 10:15:00 10:21:08
22-Feb-17 10:14:00 NS5A Resistance: The HCV genotype is la and lb. The following resistance-associated variants were identified in the la subpopulation : K24A, Q30G Elbasvir: Predicted Ledipasvir: Predicted The following resistance-associated variants were identified in the lb subpopulation : None Elbasvir: Not Predicted Ledipasvir: Not Predicted					
Resistance variants and interpretations are reported based on EASL HCV treatment guidelines (available: http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf).					
The following additional variants were also identified in the la subpopulation:Y39D The following additional variants were also identified in the lb subpopulation:A39Q In vitro and/or clinical studies have identified these additional variants as having a possible association with resistance but may require additional studies to confirm. For further information, please refer to package inserts for the applicable direct acting antiviral drug (daclatasvir, elbasvir, ledipasvir, ombitasvir and velpatasvir).					

22-Feb-17 10:14:00 NS5A Genotype: INTERPRETIVE INFORMATION: HCV NS5A Drug Resistance by Sequencing

This assay detects resistance-associated variants in NS5A codons 20-101 for HCV genotypes la and lb. Variants in viral sub-populations below 20 percent of total may not be detected. For further information, please refer to drug package inserts for the applicable direct acting antiviral drug and current HCV treatment guidelines (e.g. AASLD/IDSA guidelines or EASL HCV treatment recommendations).

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS